A metabolic profile of polyamines in parkinson disease: A promising biomarker
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objective: Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and severity‐associated PD biomarker. Methods: Comprehensive metabolome analysis of plasma was performed in Cohort A (controls, n = 45; PD, n = 145), followed by analysis of 7 polyamine metabolites in Cohort B (controls, n = 49; PD, n = 186; progressive supranuclear palsy, n = 19; Alzheimer disease, n = 23). Furthermore, 20 patients with PD who were successively examined within Cohort B were studied using diffusion tensor imaging (DTI). Association of each polyamine metabolite with disease severity was assessed according to Hoehn and Yahr stage (H&Y) and Unified Parkinson's Disease Rating Scale motor section (UPDRS‐III). Additionally, the autophagy induction ability of each polyamine metabolite was examined in vitro in various cell lines. Results: In Cohort A, N 8‐acetylspermidine and N‐acetylputrescine levels were significantly and mildly elevated in PD, respectively. In Cohort B, spermine levels and spermine/spermidine ratio were significantly reduced in PD, concomitant with hyperacetylation. Furthermore, N 1,N 8‐diacetylspermidine levels had the highest diagnostic value, and correlated with H&Y, UPDRS‐III, and axonal degeneration quantified by DTI. The spermine/spermidine ratio in controls declined with age, but was consistently suppressed in PD. Among polyamine metabolites, spermine was the strongest autophagy inducer, especially in SH‐SY5Y cells. No significant genetic variations in 5 genes encoding enzymes associated with spermine/spermidine metabolism were detected compared with controls. Interpretation: Spermine synthesis and N 1,N 8‐diacetylspermidine may respectively be useful diagnostic and severity‐associated biomarkers for PD. ANN NEUROL 2019;86:251–263
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
MR diffusion tensor spectroscopy and imaging
Basser, P. J., Mattiello, J., & LeBihan, D. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80775-1 · Cited by 5,970
SMITH, S., & NICHOLS, T. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.061 · Cited by 5,250
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice
Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R., Yokoyama, M., Mishima, K., Saito, I., Okano, H., et al. (2006) · Nature · doi:10.1038/nature04724 · Cited by 3,882 · cited 1×
“Autophagy deficiency causes neurodegeneration along with aggregated protein accumulation in the cytoplasm.(45,46) Notably, in PD, α-synuclein included in Lewy bodies is an autophagy substrate and targeted by disease-modifying therapy with autophagy-inducing chemicals.”
BackgroundLoss of autophagy in the central nervous system causes neurodegeneration in mice
Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J.-I., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006) · Nature · doi:10.1038/nature04723 · Cited by 3,500 · cited 1×
“Autophagy deficiency causes neurodegeneration along with aggregated protein accumulation in the cytoplasm.(45,46) Notably, in PD, α-synuclein included in Lewy bodies is an autophagy substrate and targeted by disease-modifying therapy with autophagy-inducing chemicals.”
BackgroundSelf-citationRubinsztein, D. C., Mariño, G., & Kroemer, G. (2011) · Cell · doi:10.1016/j.cell.2011.07.030 · Cited by 2,107
Ageing as a Risk Factor for Disease
Niccoli, T., & Partridge, L. (2012) · Current Biology · doi:10.1016/j.cub.2012.07.024 · Cited by 1,831
Cardioprotection and lifespan extension by the natural polyamine spermidine
Eisenberg, T., Abdellatif, M., Schroeder, S., Primessnig, U., Stekovic, S., Pendl, T., Harger, A., Schipke, J., Zimmermann, A., Schmidt, A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4222 · Cited by 1,168
Spermidine in health and disease
Madeo, F., Eisenberg, T., Pietrocola, F., & Kroemer, G. (2018) · Science · doi:10.1126/science.aan2788 · Cited by 1,154 · cited 5×
“Growing evidence implies that Spd is involved in antiaging through induction of autophagy.(6) Furthermore, oral Spd administration protects flies against neurodegenerationlike age-induced memory impairment and α-synuclein–induced motor dysfunction through autophagy enhancement, indicating that Spd-induced autophagy is…”
BackgroundInfluential
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
Self-citationParkinson’s Disease and Gut Microbiota
Hirayama, M., & Ohno, K. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000518147 · Cited by 158
Visualization of reactive astrocytes in living brain of Alzheimer’s disease patient
Nam, M.-H., Ko, H. Y., Lee, S., Park, Y. M., Hyeon, S. J., Won, W., Kim, S. Y., Jo, H. H., Chung, J.-I., Han, Y.-E., et al. (2021) · doi:10.1101/2021.04.13.439744 · Cited by 71
Jiang, Z., Wang, X., Zhang, H., Yin, J., Zhao, P., Yin, Q., & Wang, Z. (2023) · MedComm · doi:10.1002/mco2.268 · Cited by 50
Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease
Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., et al. (2020) · Aging · doi:10.18632/aging.103992 · Cited by 50
“Metabolomic studies performed on plasma samples, mainly focusing on idiopathic PD patients, identified new potential biomarkers in PD such as: polyamines [13], long-chain acylcarnitines [13], caffeine [49], tryptophan or bilirubin [50], glutathione or purine metabolism [14], cholesterol [9], kynurenine [15] or pyruvat…”
Background
Metadata
- Authors
- Saiki, S., Sasazawa, Y., Fujimaki, M., Kamagata, K., Kaga, N., Taka, H., Li, Y., Souma, S., Hatano, T., Imamichi, Y., Furuya, N., Mori, A., Oji, Y., Ueno, S., Nojiri, S., Miura, Y., Ueno, T., Funayama, M., Aoki, S., & Hattori, N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2019-07
- Volume
- 86
- Issue
- 2
- Pages
- 251-263
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2948899251
- Cited by
- 122
- References
- 14
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A metabolic profile of polyamines in parkinson disease: A promising biomarker. https://app.cochat.ai/papers/10.1002/ana.25516
- The paper
- Saiki, S., Sasazawa, Y., Fujimaki, M., Kamagata, K., Kaga, N., Taka, H., Li, Y., Souma, S., Hatano, T., Imamichi, Y., Furuya, N., Mori, A., Oji, Y., Ueno, S., Nojiri, S., Miura, Y., Ueno, T., Funayama, M., Aoki, S., & Hattori, N. (2019). A metabolic profile of polyamines in parkinson disease: A promising biomarker. Annals of Neurology. https://doi.org/10.1002/ana.25516
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.